PTHrP: The Hormone Hijacked by Cancer
Parathyroid and Calcium Peptides
80%
Proportion of malignancy-associated hypercalcemia cases caused by tumor-secreted PTH-related peptide, the single most common mechanism.
Potts, Journal of Endocrinology, 2005
Potts, Journal of Endocrinology, 2005
View as imageParathyroid hormone-related peptide (PTHrP) is one of the most misunderstood molecules in endocrinology. It was discovered in 1987 as the cause of humoral hypercalcemia of malignancy, the life-threatening calcium elevation that kills cancer patients. But PTHrP is not a cancer molecule. It is a normal hormone with critical roles in fetal bone development, lactation, cartilage formation, and tissue growth. Cancers hijack it. Understanding PTHrP requires separating its physiological identity from its pathological reputation. For the broader context of calcium-regulating peptides, see the pillar article on parathyroid hormone: the calcium controller.
Key Takeaways
- PTHrP shares its first 13 amino acids with PTH and binds the same receptor (PTH1R), but the two peptides have completely different physiological roles[1]
- PTHrP is essential for fetal skeletal development, directing endochondral bone formation and placental calcium transport
- Tumor-secreted PTHrP causes up to 80% of all malignancy-associated hypercalcemia cases, primarily from lung, breast, and renal cell carcinomas[2]
- Abaloparatide, an FDA-approved osteoporosis drug, is a synthetic analog of PTHrP(1-34) that reduced vertebral fracture risk by 86% compared to placebo[3]
- PTHrP has been identified as a therapeutic target in idiopathic pulmonary fibrosis, expanding its relevance beyond bone and cancer[4]
- Different PTH1R ligands (PTH, PTHrP, abaloparatide, teriparatide) activate the same receptor but produce distinct downstream signaling patterns[5]
PTHrP Is Not PTH
The name "parathyroid hormone-related peptide" implies PTHrP is a variant of PTH. It is not. PTHrP and PTH are encoded by different genes on different chromosomes. They evolved from a common ancestor, but their biology diverged substantially.
PTH is a classic endocrine hormone: it is made in one place (the parathyroid glands), released into the blood, and acts on distant targets (bone and kidney) to raise blood calcium. PTHrP operates differently. It is produced locally in dozens of tissues, including cartilage, breast, smooth muscle, skin, and brain, where it acts in a paracrine or autocrine fashion. Under normal circumstances, PTHrP does not circulate in measurable amounts in adults.[1]
The structural overlap is limited but functionally critical. PTHrP shares 8 of its first 13 amino acids with PTH, and this N-terminal region is what binds PTH1R, the shared receptor. Beyond position 13, the sequences diverge completely. Full-length PTHrP is 141 amino acids (with alternative splice variants producing 139- and 173-amino-acid forms), while PTH is only 84 amino acids. The "mid-molecule" region of PTHrP (residues 35-84) has functions that PTH does not share, including stimulating placental calcium transport.[2]
Martin and colleagues provided a comprehensive review of the physiological and pharmacological roles of both PTH and PTHrP acting through PTH1R, clarifying how two peptides with such different biological identities can share a single receptor.[1] The answer lies in receptor conformation. PTH1R exists in multiple conformational states, and PTH versus PTHrP stabilize different conformations, triggering different durations of intracellular signaling despite binding the same protein.
PTHrP in Normal Physiology
Fetal Bone Development
PTHrP is indispensable for skeletal formation. During fetal development, chondrocytes (cartilage cells) in the growth plate produce PTHrP, which acts locally to regulate the pace of cartilage-to-bone conversion (endochondral ossification). PTHrP keeps chondrocytes in a proliferative state, preventing them from differentiating into hypertrophic cells too rapidly. Without PTHrP signaling, the growth plate collapses prematurely, and bones form abnormally short and dense.[1]
Animal models with PTHrP gene deletion die at birth with severe skeletal abnormalities. The cartilage-bone interface in long bones fails to develop properly, confirming that PTHrP is not just helpful for bone formation but essential.
Lactation and Calcium Mobilization
During breastfeeding, the mammary gland produces large amounts of PTHrP that enter the maternal circulation. This is one of the rare situations where PTHrP acts as a true hormone rather than a local signaling molecule. Circulating PTHrP mobilizes calcium from the mother's skeleton, ensuring adequate calcium supply for milk production. Lactating women can lose 3-10% of their bone mineral density during breastfeeding, much of it driven by PTHrP-mediated bone resorption. This bone loss is normally recovered after weaning.
Other Tissues
PTHrP plays roles in smooth muscle relaxation (uterus, blood vessels, bladder), tooth eruption, mammary gland development (during embryonic life, PTHrP drives mammary mesenchyme specification and nipple formation), skin differentiation, and hair follicle cycling. It is expressed in virtually every tissue that has been examined, which is why cancer in nearly any organ has the potential to overproduce it.
How Cancer Hijacks PTHrP
The Mechanism of Humoral Hypercalcemia
When a tumor produces PTHrP in excess, the peptide floods the circulation and acts on the same PTH1R receptors that PTH normally activates. The result mimics severe hyperparathyroidism: calcium pours out of bone into the blood, the kidneys reabsorb more calcium instead of excreting it, and serum calcium rises to dangerous levels.[2]
PTHrP-mediated hypercalcemia accounts for approximately 80% of all malignancy-associated hypercalcemia. The cancers most commonly responsible are squamous cell carcinomas of the lung, head, and neck; renal cell carcinoma; breast cancer; and urothelial carcinomas. Hematological malignancies (lymphoma, leukemia) can also produce PTHrP, though less frequently.
Foley and colleagues reported a case of PTHrP secretion from a pancreatic neuroendocrine tumor, illustrating that even rare tumor types can cause this syndrome.[6] Zueva and colleagues described two contrasting cases of metastatic PTHrP-secreting pancreatic neuroendocrine tumors, highlighting the challenges of managing both the hormonal syndrome and oncological progression simultaneously.[7]
Why Hypercalcemia Is Dangerous
Mild hypercalcemia causes fatigue, constipation, and confusion. Severe hypercalcemia (calcium above 14 mg/dL) causes cardiac arrhythmias, renal failure, coma, and death. In cancer patients, hypercalcemia is a prognostic marker: median survival after diagnosis of malignant hypercalcemia is measured in weeks to months, though this reflects the advanced stage of cancer rather than the hypercalcemia itself.
Treatment targets both the calcium elevation (intravenous fluids, bisphosphonates, denosumab) and the underlying cancer. Reducing tumor burden lowers PTHrP production. In refractory cases, PTHrP itself becomes a potential therapeutic target, though no PTHrP-specific inhibitor has reached clinical use.
PTHrP and Bone Metastasis
PTHrP also plays a direct role in skeletal metastasis, particularly in breast cancer. Cancer cells that metastasize to bone produce PTHrP locally, which stimulates osteoclastic bone resorption around the metastatic deposit. The dissolved bone releases growth factors (TGF-beta, IGFs) that feed back to the cancer cells, promoting their survival and further PTHrP production. This "vicious cycle" of bone destruction and tumor growth is a central mechanism in osteolytic bone metastases. For more on how peptides interact with bone biology, see calcitonin: the thyroid peptide that protects your bones.
Abaloparatide: Turning PTHrP Into Medicine
The same receptor biology that cancer exploits has been repurposed for osteoporosis therapy. Abaloparatide is a synthetic 34-amino-acid peptide analog of PTHrP(1-34), modified to preferentially bind the RG conformation of PTH1R rather than the R0 conformation. This distinction is pharmacologically meaningful.
Receptor Conformation and Signaling Duration
Hattersley and colleagues demonstrated that abaloparatide binds selectively to the RG (G protein-dependent) conformation of PTH1R, producing a shorter duration of cAMP signaling compared to teriparatide (PTH 1-34), which also engages the R0 (G protein-independent) conformation and produces more prolonged signaling.[5]
Sato and colleagues compared the intracellular signaling pathways activated by teriparatide, abaloparatide, and long-acting PTH, finding that initial receptor engagement was comparable across ligands but that downstream signaling duration and pathway selection differed.[8] The practical consequence is that abaloparatide preferentially stimulates bone formation over bone resorption, a more favorable therapeutic ratio than teriparatide.
Clinical Results
Leder and colleagues reported the phase II results of abaloparatide in postmenopausal women with osteoporosis, showing dose-dependent increases in bone mineral density at the lumbar spine and total hip over 24 weeks.[9] The subsequent phase III ACTIVE trial demonstrated an 86% reduction in vertebral fracture risk and a 43% reduction in nonvertebral fracture risk compared to placebo over 18 months. Miller and colleagues reviewed the complete clinical evidence for abaloparatide, confirming its position as an anabolic osteoporosis treatment.[3]
Abaloparatide was FDA-approved in 2017 under the brand name Tymlos. It is administered as a daily subcutaneous injection, the same route as teriparatide (Forteo). For a detailed comparison of these two PTH1R-targeting peptides, see how peptide drugs for osteoporosis compare: teriparatide vs abaloparatide.
PTHrP Beyond Bone and Cancer
Pulmonary Fibrosis
Fang and colleagues identified PTHrP as a therapeutic target in idiopathic pulmonary fibrosis (IPF), a progressive lung disease with limited treatment options.[4] Their work demonstrated that PTHrP mediates crosstalk between immune or alveolar epithelial cells and fibroblasts, contributing to the pathological fibrotic remodeling that characterizes IPF. Targeting PTHrP signaling in the lung could represent a new therapeutic approach, though this remains preclinical.
This finding reinforces a broader principle: PTHrP is active in far more tissues than its name suggests. Its involvement in lung fibrosis, mammary development, smooth muscle biology, and hair cycling means that any therapeutic intervention targeting PTHrP must account for potential off-target effects in these tissues. PTHrP is one member of a broader family of calcium-regulating peptides that includes calcitonin and its gene-related product CGRP; for how the calcitonin gene produces both a bone-protective hormone and a migraine mediator, see CGRP: from calcitonin gene to migraine target.
Tooth Development and Eruption
PTHrP produced by cells of the tooth follicle is required for normal tooth eruption. It stimulates the osteoclastic bone resorption that creates the eruption pathway through the jawbone. Disruption of local PTHrP signaling can prevent teeth from erupting, a finding that has implications for understanding impacted teeth and dental abnormalities.
Measuring PTHrP Clinically
PTHrP is measured in plasma using immunometric assays. Normal circulating levels in adults are below the detection limit of most assays (below 2.0 pmol/L). Elevated levels indicate either malignancy-associated production or, rarely, benign conditions like lactation or phaeochromocytoma.
The clinical indication for measuring PTHrP is to differentiate humoral hypercalcemia of malignancy from primary hyperparathyroidism. Both conditions present with high calcium, but PTH is elevated in hyperparathyroidism and suppressed in PTHrP-mediated hypercalcemia (because high calcium suppresses normal parathyroid gland function). A high PTHrP with suppressed PTH confirms the malignant cause.
Limitations of Current Understanding
No anti-PTHrP therapy exists. Despite PTHrP being the proximate cause of malignant hypercalcemia in the majority of cases, no drug specifically blocks PTHrP production or PTHrP-PTH1R interaction. Treatment relies on downstream interventions (bisphosphonates, denosumab) and treating the underlying cancer.
The dual role in cancer is poorly understood. Evidence suggests PTHrP may actually suppress tumor growth in early-stage cancer through autocrine signaling, while promoting metastasis in later stages through paracrine effects on bone. How and when PTHrP switches from tumor suppressor to tumor promoter is not resolved.
Lactation bone loss. The clinical significance of PTHrP-driven bone loss during breastfeeding is debated. Most bone mineral density recovers after weaning, but whether prolonged or repeated lactation periods create lasting skeletal deficits is unclear.
The Bottom Line
PTHrP is a multifunctional peptide that controls fetal bone development, drives calcium mobilization during lactation, and regulates tissue growth across dozens of organs. Cancer cells exploit PTHrP by overproducing it, causing the dangerous calcium elevations that complicate malignancy. The same receptor biology has been harnessed therapeutically: abaloparatide, a synthetic PTHrP analog, is an FDA-approved osteoporosis treatment that reduces fracture risk by preferentially stimulating bone formation. New research implicates PTHrP in pulmonary fibrosis, expanding the clinical relevance of this underappreciated peptide.